According to our analysis, a  short position is recommended for this stock.  All the technical indicators and moving averages depict a potential sell signal for CVAC.
CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

For more details click on the attached report below. 

Research Team | Finance Club UoM